Business context and reporting period
The source filing is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018. The request metadata names Alaunos Therapeutics, Inc.; investors should confirm the issuer and filing identity. Ziopharm was a clinical-stage biopharmaceutical company developing immuno-oncology therapies, principally Controlled IL-12 and Sleeping Beauty gene- and cell-therapy platforms. It had no approved products and described its revenue as minimal.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 or prior date |
|---|---|---|
| Collaboration revenue | $0.146 million | $1.597 million |
| Research and development expense | $10.183 million | $11.967 million |
| General and administrative expense | $6.159 million | $3.595 million |
| Operating loss | $16.196 million | $13.965 million |
| Net loss | $16.020 million | $15.487 million |
| Net loss applicable to common stockholders | $21.140 million | $19.658 million |
| Basic and diluted loss per share | $0.15 | $0.15 |
| Cash and cash equivalents | $51.108 million | $70.946 million at Dec. 31, 2017 |
| Working capital | $62.0 million | $69.9 million at Dec. 31, 2017 |
| Operating cash used | $18.957 million | $14.277 million |
Cash, cash equivalents and restricted cash totaled $51.497 million at quarter-end. Investing activities used $0.150 million; financing activities used $0.731 million, primarily for restricted-stock repurchases. The filing reports no conventional borrowings; reported liabilities were $61.571 million, including $49.513 million of contract liabilities and $2.469 million of derivative liabilities. Losses make conventional profit margins not meaningful.
Material changes versus the prior comparable period
- Revenue fell 91%, primarily because adoption of ASC 606 changed the timing of recognition for the Ares Trading collaboration payment; it was not described as a comparable change in cash receipts.
- Research and development expense declined 15%, reflecting lower gene-therapy, GvHD and cell-therapy program costs.
- General and administrative expense rose 71%, primarily due to stock compensation and employee-related expense associated with option modifications for a departing officer and a director. Total stock-based compensation was $3.659 million, including $0.481 million from option-life extensions.
- Operating cash use increased by $4.680 million year over year. Cash and cash equivalents declined by $19.838 million from year-end, including restricted cash in the cash-flow reconciliation.
- Common-stockholder loss increased despite reported net loss being relatively similar, reflecting higher preferred-stock dividends.
Outlook, management commentary, risks and unusual items
- Management estimated that available cash would fund planned operations into the second quarter of 2019. There were no committed additional financing sources, and management stated that substantial doubt existed about the company’s ability to continue as a going concern. Additional capital or partnerships would be needed; failure to obtain them could require curtailing development.
- No formal financial forecast was provided. Management said it had delayed initiation of the planned pivotal Controlled IL-12 study while pursuing additional studies, including a Phase 1 combination study with nivolumab in recurrent glioblastoma.
- Management anticipated a point-of-care Sleeping Beauty CAR-T Phase 1 study at MD Anderson and an NCI-led Sleeping Beauty TCR Phase 1 study in the second half of 2018, subject to regulatory and operational readiness.
- Management cited preliminary, small-sample clinical evidence for Controlled IL-12, including median overall survival of 12.5 months among 15 patients treated at a specified dose, with mean follow-up of 11.1 months. The filing cautions that interim results may not predict final trial results; the comparison was to historical outcomes.
- ASC 606 adoption on January 1, 2018 produced an $8.131 million cumulative adjustment to opening accumulated deficit and increased the contract liability. The standard also reduced Q1 2018 reported collaboration revenue by $1.451 million relative to the prior accounting guidance.
- Series 1 preferred stock held by Precigen accrued dividends in additional preferred shares. The company issued 3,624 dividend shares in the quarter; the preferred stock had a $149.0 million carrying amount and a $147.9 million stated liquidation value. Conversion and liquidation rights, ongoing dividends and potential dilution are material considerations.
- Key risks include dependence on future financing, clinical and regulatory uncertainty, competition, manufacturing and supply constraints, and dependence on licensed technology and collaborators. The company had discontinued its GvHD development effort and was winding down related activities.
Important facts for investors to verify
- Confirm whether this Ziopharm filing is the intended filing for the Alaunos Therapeutics request.
- Check subsequent cash use, financing, and whether the projected runway into Q2 2019 was achieved.
- Review the accounting impact of ASC 606 and the remaining Ares Trading contract liability, reported at $49.5 million.
- Track clinical-trial progress and outcomes against management’s stated timelines, with particular attention to final data and trial size.
- Assess the Series 1 preferred stock’s dividend accrual, conversion and liquidation terms, and resulting potential dilution to common shareholders.
- Review the full filing and subsequent disclosures for updated going-concern, financing, collaboration, and material-risk information.